Summary of Study ST002498
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001613. The data can be accessed directly via it's Project DOI: 10.21228/M86H7K This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
| Study ID | ST002498 |
| Study Title | Plasma Metabolomics Profiling of 580 Patients from the Weill Cornell Medicine Early Detection Research Network Prostate Cancer Cohort |
| Study Summary | Prostate cancer is the second most common cancer in men and affects 1 in 9 men in the United States. Early screening for prostate cancer often involves monitoring levels of prostate-specific antigen (PSA) and performing digital rectal exams. However, a prostate biopsy is always required for definitive cancer diagnosis. The Early Detection Research Network (EDRN) is a consortium within the National Cancer Institute aimed at improving screening approaches and early detection of cancers. As part of this effort, the Weill Cornell EDRN Prostate Cancer has collected and biobanked specimens from men undergoing a prostate biopsy between 2008 and 2017. In this report, we describe blood metabolomics measurements for a subset of this population. The dataset includes detailed clinical and prospective records for 580 patients who underwent prostate biopsy, 287 of which were subsequentially diagnosed with prostate cancer, combined with profiling of 1,482 metabolites from plasma samples collected at the time of biopsy. We expect this dataset to provide a valuable resource for scientists investigating prostate cancer metabolism. |
| Institute | Weill Cornell Medicine |
| Last Name | Krumsiek |
| First Name | Jan |
| Address | 1305 York Avenue, New York, NY 10021 |
| jak2043@med.cornell.edu | |
| Phone | 646-962-4152 |
| Submit Date | 2023-02-24 |
| Total Subjects | 580 |
| Num Males | 580 |
| Analysis Type Detail | LC-MS |
| Release Date | 2023-09-19 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Collection:
| Collection ID: | CO002947 |
| Collection Summary: | The Weill Cornell EDRN Prostate Cancer Cohort consented and recruited 1,144 patients (518 cases and 626 controls) over 9 years (from 2008 to 2017). In order to be eligible for the study, patients needed to be adult males, have no prior history of prostate cancer or prostate biopsies, and be scheduled to undergo prostate biopsy at Weill Cornell Medicine in New York City. Need of prostate biopsy was determined based on suspicion of prostate cancer, which primarily included elevated PSA levels, abnormal digital rectal exam (DRE) results, or suspicious findings based on imaging. Prostate biopsies included at least 10 cores taken in a laterally directed fashion, and a fasting blood sample was collected prior to prostate biopsy from all recruited patients. Biopsy tissue, together with urine and blood samples were processed and biobanked at Weill Cornell Medicine. For each patient, extensive clinical parameters were collected, including biopsy results, prostate cancer diagnosis and 2-year follow-up clinical information. EDTA-plasma samples for metabolomics profiling were selected to include patients with complete 12- and 24-months follow-up information available (see Data Records section for more details). This subset included a total of 580 patients, with 267 men diagnosed with PCa and 313 controls. |
| Sample Type: | Blood (plasma) |
